A European Platform for MDMA Integration
Across Europe, growing attention is being directed toward MDMA-assisted psychotherapy in treatment of trauma-related mental health conditions. Clinical research, most notably in post-traumatic stress disorder (PTSD), has generated an expanding body of evidence. At the same time, translation of this research into routine mental health care remains limited, shaped by regulatory constraints and the continued classification of MDMA as a controlled substance in most European countries. These conditions create significant clinical and regulatory complexity, even within carefully governed settings.
European Alignment
Established in 2024, the European Platform for Integration of MDMA in Mental Health Care (EPIC) emerged in response to the persistent gap between clinical research and real-world mental health systems. The initiative brings together clinicians, researchers, and policy experts to support careful, informed consideration of how MDMA-assisted psychotherapy, particularly in the treatment of PTSD, might be approached within European mental health care frameworks, should regulatory conditions permit.
European Innovation
EPIC is not an advocacy movement and does not promote access to or implementation of MDMA-assisted psychotherapy. Its role is to function as a structured convening initiative that brings clinical experience, scientific evidence, and regulatory perspectives into dialogue around shared questions of safety, ethics, and system readiness within mental health care. Through engagement with national and European stakeholders, EPIC addresses issues related to regulatory coherence, clinical standards, and professional preparedness. Throughout this work, the emphasis remains on patient safety, clinical integrity, and the preservation of long-term public trust as essential foundations for any responsible consideration of medical integration.
European Initiative
EPIC operates as a convening and coordination initiative. It does not provide clinical services, deliver training programs, or advocate for specific regulatory outcomes. Its role is to support informed dialogue and alignment among clinicians, researchers, and policymakers on questions related to the potential medical integration of MDMA-assisted psychotherapy within European mental health care systems. EPIC’s work is conditional by design, grounded in evidence, ethics, and regulatory reality rather than timelines or implementation commitments.